COVID-19Hospitals

Health System in Pandemic Epicenter Identifies Outcomes and New Risk Factors of Patients Hospitalized with COVID-19

NEW YORK, May 26, 2020 /PRNewswire/ — A team of investigators at NYU Langone Health determined that just over half of 5,279 patients who tested positive for COVID-19 were hospitalized — and nearly a quarter of those hospitalized died or were discharged to hospice, including 60 percent who required ventilators.

The study —  recently published online in The BMJ — is the most complete report of outcomes for COVID-19 hospitalized patients in the United States to date, according to the authors.  The investigators found that while age and comorbidities were strong predictors of hospitalization, critical illness and death, patients with low levels of blood oxygen (88 percent or lower) upon admission, and those with markers of inflammation such as elevations in c-reactive protein (a substance produced by the liver in response to inflammation), were most likely to have the worst outcomes during hospitalization. 

“Our findings provide a rich understanding of the characteristics of people most at risk for poor outcomes once they are hospitalized with COVID-19,” says Leora Horwitz, MD, associate professor in the Departments of Population Health and Medicine, director of the Center for Healthcare Innovation and Delivery Science at NYU Langone Health, and the study’s senior author. “We demonstrated that age, being male, being severely obese and having certain chronic diseases like heart failure and kidney disease put patients at high risk for hospitalization for COVID-19. We also showed that the degree of oxygen impairment and markers of inflammation in patients were most strongly associated with poor outcomes during hospitalization.”

As a result, Horwitz says clinicians should routinely test COVID-19 patients for inflammatory markers throughout their hospitalization. Another challenge, according to Horwitz, is that many study patients did not notice their oxygen levels were low. “If more people could monitor oxygen levels at home and come to the hospital earlier, perhaps that could improve their outcomes,” says Horwitz.

Responding to a Pandemic: How the Study Was Conducted

Investigators obtained all data from NYU Langone’s electronic health record (EHR) of inpatient and outpatient visits at the system’s 260 outpatient office sites and four acute care hospitals in Manhattan, Brooklyn, and Long Island. For data on tobacco use, body mass index (BMI) and comorbidities, the researchers included data in the EHR entered during prior inpatient or outpatient visits.

The research team assessed three primary outcomes: inpatient hospitalization; critical illness (defined as care in the intensive care unit, the use of mechanical ventilation, discharge to hospice, or death); and discharge to hospice or death among hospitalized patients. The study was conducted between March 1, 2020 and April 8, 2020. The final date of follow up was May 5, 2020.

Study Findings

  • Of 5,279 patients who tested positive for COVID-19, 2,741 (51.9 percent) were hospitalized, 1,904 (69.5 percent) were discharged, and 665 (24.3 percent) died or were discharged to hospice.
  • Of 647 (23.6 percent) hospitalized patients who required ventilators, 391 (60.4 percent) died and 170 (26.2 percent) were discharged.
  • The strongest risk for hospitalization was age (40 percentage points increased risk for patients 65-74, and 58 percentage points increased risk for patients 75 years or older).
  • The strongest risk factors for developing critical illness — besides age — were heart failure, chronic kidney disease, body mass index greater than 40, and sex (male over female). However, blood oxygen levels below 88 percent upon admission and markers of inflammation were more strongly associated with critical illness than age and comorbidities.    
  • 53 percent of hospitalized adult patients were younger than 65 years of age.
  • Risk of critical illness and death among hospitalized patients decreased significantly during the study period–suggesting that the ability to care for these patients improved, even without definitive “game changing” drugs.

Certain findings, according to lead author Christopher M. Petrilli, MD, assistant professor, Department of Medicine at NYU Langone Health, and colleagues, were more difficult to explain.

“We were expecting that asthma or COPD would increase risk of both hospitalization and critical illness, but the risk was much smaller than what we were expecting,” said Petrilli. “Meanwhile, patients with heart failure and chronic kidney disease were at much higher risk. We still don’t really understand why certain diseases seem to put people at more risk than others.”

“While we continue to study outcomes in patients who tested positive for COVID-19 to create reliable real-time tools, the next phase of investigation will be development of predictive risk models to build into provider workflows, analyzing differences in outcomes across different hospitals to identify best clinical practices, and, finally, looking at non-COVID patients who may have delayed medical care from being fearful to come to the hospital,” Petrilli says.

Despite age being the greatest risk for hospitalization, critical illness, and death, Horwitz cautions everyone to take COVID-19 seriously. “It’s important to distinguish population risk from individual risk,” she says. “If you are young, that doesn’t mean that you can’t get the virus. Almost a third of our hospitalized patients are younger than 55. Similarly, having chronic diseases increases risk, but one in five of our hospitalized patients had no chronic conditions.”

In addition to Horwitz and Petrilli, additional co-authors from NYU Langone Health are Simon A. Jones, PhD, Jie Yang, MPH, MS, Harish Rajagopalan, Luke O’Donnell, MD, Yelena Chernyak, Katie Tobin, MPH, Robert J. Cerfolio, MD, and Fritz Francois, MD. Funding for the study was provided in part by the Kenneth C. Griffin Charitable Fund.

Media Inquiries:

Sasha Walek
646-501-3873
Sasha.Walek@nyulangone.org 

SOURCE NYU Langone Health

Related Links

http://www.med.nyu.edu

Print Friendly, PDF & Email
Tags

Mike Adams

Mike Adams is a medical device sales leader with extensive clinical experience in spine and biologics and a nationwide distribution network built over the last 10+ years in the industry. He has held various leadership positions in healthcare and device including Distributor Partner, Hospital COO and Spine VP of Sales. He currently leads the commercialization strategy for OrthoSpine Partners and is a Distributor Principal at Novel Medical. Because of his unique career path, Mike has the ability to see the healthcare business from multiple perspectives making him passionate about building strategic partnerships that help reduce overall costs, drive innovation, and cultivate growth for new markets.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button
Close